The VALID trial, sponsored by Queen's University, focuses on a volunteer-led program aimed at addressing neuropsychiatric symptoms in dementia patients, specifically those with Alzheimer's disease. Given the increasing prevalence of dementia and the limited efficacy of pharmacological treatments, this program could represent a significant advancement in non-pharmacological care strategies. The outcomes may enhance patient quality of life and reduce caregiver and staff stress, potentially positioning the VALID program as a scalable model for long-term care facilities. The market for dementia care solutions is expanding, and successful results could lead to partnerships with healthcare providers and potential funding opportunities. Competitive implications include the need to monitor similar initiatives in the non-pharmacological space, particularly those that leverage volunteer engagement.